68Ga-RM26 PET/CT对68Ga-PSMA-617 PET/CT评估mCRPC患者ARSIs治疗后转归的附加价值
这项回顾性单中心研究纳入44例同时接受68Ga-PSMA-617 PET/CT与68Ga-RM26 PET/CT扫描的mCRPC患者,按病灶GRPR状态分为两组,比较ARSIs治疗后的最大PSA反应率与无进展生存期。GRPR+组中位最大PSA反应率为37.78%、中位PFS为8.9个月,均低于GRPR-组的69.39%和14.37个月。
要点
- 44例中41例PSMA摄取阳性、23例GRPR摄取阳性,3例仅GRPR摄取阳性。
- GRPR+组中位最大PSA反应率37.78%,低于GRPR-组的69.39%。
- GRPR+组中位PFS 8.9个月,短于GRPR-组的14.37个月。
核心结论
- 与GRPR-患者相比,GRPR+病灶的mCRPC患者ARSIs治疗后中位最大PSA反应率更低、中位PFS更短,提示该亚组治疗反应较差、预后相对更差。
研究设计与样本
- 回顾性单中心研究,纳入同时接受68Ga-PSMA-617 PET/CT和68Ga-RM26 PET/CT扫描的患者,共44例。
- 依据病灶GRPR状态(阳性/阴性)将患者分为两组,比较ARSIs治疗后的最大PSA反应率和PFS。
主要发现
- 44例中41例显示PSMA摄取、23例显示GRPR摄取,3例仅显示GRPR摄取。
- GRPR+组中位最大PSA反应率为37.78%,GRPR-组为69.39%,GRPR+组低于GRPR-组。
- GRPR+组中位PFS为8.9个月,GRPR-组为14.37个月,GRPR+组短于GRPR-组。
- 多因素分析显示,GRPR状态、远处淋巴结转移(LNM)和骨转移病灶PSMA SUVmax是PSA反应率的显著预测因素。
- GRPR状态和区域淋巴结转移灶PSMA SUVmax是PFS的显著预测因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Besides its potential as a PET/CT tracer, the Gastrin-Releasing Peptide Receptor (GRPR) has been shown to predict the prognosis of Prostate Cancer (PCa). Herein, we aimed to evaluate the additive ability of 68Ga-RM26 PET/CT as a tracer to predict the prognosis of patients with metastatic Castration-Resistant Prostate Cancer (mCRPC) following Androgen Receptor Signal Inhibitors (ARSIs) therapy. METHODS: This retrospective single-center study involved patients who underwent both 68Ga-PSMA-617 PET/CT and 68Ga-RM26 PET/CT scans. Based on the GRPR status of their lesions (positive/negative), the patients were stratified into two cohorts, and their actual prognosis was assessed by comparing their maximum Prostate-Specific Antigen (PSA) response rates and Progression-Free Survival (PFS) durations following ARSI therapy. RESULTS: This study involved 44 patients. Among them, 41 and 23 showed PSMA uptake and GRPR uptake, respectively, with 3 exhibiting GRPR uptake alone. The GRPR + group had an median PSA response rate of 37.78% and a median PFS duration of 8.9 months, both of which were significantly lower than those of GRPR- patients, whose corresponding values were 69.39% and 14.37 months, respectively. According to the multivariate analysis results, GRPR status, distant Lymph Node Metastasis (LNM) and PSMA SUVmax of bone metastases lesions were significant predictors of the PSA response rate. Furthermore, the GRPR status and PSMA SUVmax of regional lymph node metastases were significant predictors of PFS. CONCLUSION: Compared to GRPR- patients, mCRPC patients with GRPR + lesions exhibited a lower median maximum PSA response rate and a shorter median PFS duration following ARSI treatment, implying a poorer response to therapy and relatively worse prognosis in the latter subgroup.
引用
- Liu X, Qi L, Gao X, et al. The additive value of 68Ga-RM26 PET/CT to 68Ga-PSMA-617 PET/CT in assessing Post-treatment outcomes of ARSIs in mCRPC patients. Eur J Nucl Med Mol Imaging. 2025. PMID: 40518457. doi:10.1007/s00259-025-07407-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。